Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Smoldering myeloma: highlights from ASH 2020

Irene Ghobrial • 16 Dec 2020
ASH 2020
Multiple Myeloma Rare Diseases Smoldering Myeloma Carfilzomib Dexamethasone Lenalidomide Venetoclax
FORTE IFM 2009 iMMunocell

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the latest developments in the treatment of multiple myeloma as presented at ASH 2020. Dr Ghobrial highlights key research including the iMMunocell study investigating circulating tumor cell (CTC) counts and immune monitoring for the treatment of smoldering multiple myeloma (SMM), as well as research demonstrating the importance of depth of response for patients with SMM receiving carfilzomib plus lenalidomide and dexamethasone (KRd) treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Irene Ghobrial

0:52
Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial • 7 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
Early interception in SMM & novel agents being explored
Irene Ghobrial et al. • 25 Mar 2024
1:19
Single-cell sequencing of circulating tumor cells to predict progression from MGUS/SMM
Irene Ghobrial • 11 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals